{"id":17042,"date":"2024-12-07T01:16:14","date_gmt":"2024-12-06T17:16:14","guid":{"rendered":"https:\/\/flcube.com\/?p=17042"},"modified":"2024-12-07T01:16:18","modified_gmt":"2024-12-06T17:16:18","slug":"ai-proteins-partners-with-bristol-myers-squibb-to-develop-miniprotein-based-therapeutics","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=17042","title":{"rendered":"AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics"},"content":{"rendered":"\n

US-based biotech AI Proteins, Inc. has entered into a research collaboration and option agreement with New York-headquartered Bristol-Myers Squibb (BMS; NYSE: BMY<\/a>). This partnership allows BMS to explore and develop novel miniprotein-based therapeutics using AI Proteins’ advanced discovery platform.<\/p>\n\n\n\n

Agreement Terms and Financials<\/strong>
Under the terms of the agreement, AI Proteins will receive an upfront cash payment to discover and optimize miniproteins targeting two undisclosed therapeutic areas. BMS has the option to secure an exclusive worldwide license for these miniproteins, along with two additional target options. In exchange for this, BMS will pay an expansion fee and potential development, regulatory, and commercial milestone payments valued up to USD 400 million, plus royalties on net sales.<\/p>\n\n\n\n

AI Proteins: Pioneering Computational De Novo Protein Design<\/strong>
Founded in 2021, AI Proteins is a biotechnology company specializing in the use of computational de novo protein design to create therapeutic miniproteins. The company leverages AI-based design and a high-throughput drug discovery platform to optimize miniproteins for a variety of therapeutic applications, positioning it at the forefront of innovative drug development.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based biotech AI Proteins, Inc. has entered into a research collaboration and option agreement with…<\/p>\n","protected":false},"author":1,"featured_media":17047,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[99,2642,429,428,849],"class_list":["post-17042","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ai","tag-ai-proteins","tag-bms","tag-bristol-myers-squibb","tag-nyse-bmy"],"yoast_head":"\nAI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based biotech AI Proteins, Inc. has entered into a research collaboration and option agreement with New York-headquartered Bristol-Myers Squibb (BMS; NYSE: BMY). This partnership allows BMS to explore and develop novel miniprotein-based therapeutics using AI Proteins' advanced discovery platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=17042\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics\" \/>\n<meta property=\"og:description\" content=\"US-based biotech AI Proteins, Inc. has entered into a research collaboration and option agreement with New York-headquartered Bristol-Myers Squibb (BMS; NYSE: BMY). This partnership allows BMS to explore and develop novel miniprotein-based therapeutics using AI Proteins' advanced discovery platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=17042\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-06T17:16:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-06T17:16:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0611.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"769\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17042#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17042\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics\",\"datePublished\":\"2024-12-06T17:16:14+00:00\",\"dateModified\":\"2024-12-06T17:16:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17042\"},\"wordCount\":187,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17042#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0611.png\",\"keywords\":[\"AI\",\"AI Proteins\",\"BMS\",\"Bristol-Myers Squibb\",\"NYSE: BMY\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=17042#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17042\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=17042\",\"name\":\"AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17042#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17042#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0611.png\",\"datePublished\":\"2024-12-06T17:16:14+00:00\",\"dateModified\":\"2024-12-06T17:16:18+00:00\",\"description\":\"US-based biotech AI Proteins, Inc. has entered into a research collaboration and option agreement with New York-headquartered Bristol-Myers Squibb (BMS; NYSE: BMY). This partnership allows BMS to explore and develop novel miniprotein-based therapeutics using AI Proteins' advanced discovery platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17042#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=17042\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17042#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0611.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0611.png\",\"width\":1080,\"height\":769,\"caption\":\"AI Proteins Partners with Bristol Myers Squibb to Develop Miniprotein-Based Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17042#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics - Insight, China's Pharmaceutical Industry","description":"US-based biotech AI Proteins, Inc. has entered into a research collaboration and option agreement with New York-headquartered Bristol-Myers Squibb (BMS; NYSE: BMY). This partnership allows BMS to explore and develop novel miniprotein-based therapeutics using AI Proteins' advanced discovery platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=17042","og_locale":"en_US","og_type":"article","og_title":"AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics","og_description":"US-based biotech AI Proteins, Inc. has entered into a research collaboration and option agreement with New York-headquartered Bristol-Myers Squibb (BMS; NYSE: BMY). This partnership allows BMS to explore and develop novel miniprotein-based therapeutics using AI Proteins' advanced discovery platform.","og_url":"https:\/\/flcube.com\/?p=17042","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-06T17:16:14+00:00","article_modified_time":"2024-12-06T17:16:18+00:00","og_image":[{"width":1080,"height":769,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0611.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=17042#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=17042"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics","datePublished":"2024-12-06T17:16:14+00:00","dateModified":"2024-12-06T17:16:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=17042"},"wordCount":187,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=17042#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0611.png","keywords":["AI","AI Proteins","BMS","Bristol-Myers Squibb","NYSE: BMY"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=17042#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=17042","url":"https:\/\/flcube.com\/?p=17042","name":"AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=17042#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=17042#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0611.png","datePublished":"2024-12-06T17:16:14+00:00","dateModified":"2024-12-06T17:16:18+00:00","description":"US-based biotech AI Proteins, Inc. has entered into a research collaboration and option agreement with New York-headquartered Bristol-Myers Squibb (BMS; NYSE: BMY). This partnership allows BMS to explore and develop novel miniprotein-based therapeutics using AI Proteins' advanced discovery platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=17042#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=17042"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=17042#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0611.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0611.png","width":1080,"height":769,"caption":"AI Proteins Partners with Bristol Myers Squibb to Develop Miniprotein-Based Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=17042#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0611.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17042"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17042\/revisions"}],"predecessor-version":[{"id":17048,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17042\/revisions\/17048"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/17047"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17042"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17042"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}